Ki-67 is a biological tumor marker that reflects tumor
|
|
- Rosamond Stevens
- 5 years ago
- Views:
Transcription
1 Evaluation of Ki-67 Index in Core Needle Biopsies and Matched Breast Cancer Surgical Specimens Soomin Ahn, MD; Junghye Lee, MD; Min-Sun Cho, MD, PhD; Sanghui Park, MD, PhD; Sun Hee Sung, MD, PhD Context. The Ki-67 index is strongly prognostic and is used as a surrogate marker to distinguish luminal A from luminal B breast cancer types. Objective. To investigate differences in Ki-67 index between core needle biopsy samples and matched surgical samples in breast cancer. Design. We included patients with invasive breast cancer who did not receive neoadjuvant therapy. A total of 89 pairs of core needle biopsies and surgical specimens were collected, and the Ki-67 index was assessed in hot spot areas using an image analyzer. We applied a 14% Ki- 67 index to define low versus high groups. Results. The Ki-67 index was significantly higher in core needle biopsies than in surgical specimens (P,.001), with a median absolute difference of 3.5%. When we applied 14% as a cutoff, 16 of 89 cases (18%) showed discrepancy. Thirteen cases showed a high Ki-67 index in core needle biopsies but a low Ki-67 index in surgical samples. There were 10 cases (11.2%) that showed discordant luminal A/B types between core needle biopsy and the matched surgical specimen. The reasons for the discordance were poor staining of MIB1 accompanied by fixation issues and intratumoral heterogeneity of the Ki-67 index. Conclusions. A significant difference in the Ki-67 index between core biopsy and surgical specimens was observed. Our findings indicate that it may be better to perform the Ki-67 assay on the core needle biopsy and the surgical specimen than on only one sample. (Arch Pathol Lab Med. 2018;142: ; doi: / arpa oa) Ki-67 is a biological tumor marker that reflects tumor proliferation. In breast cancer, the Ki-67 index is strongly prognostic 1 and supplies additional useful information. For the purpose of prognostication and treatment decision making, breast tumors are grouped into surrogate intrinsic subtypes, defined by routine histology and immunohistochemistry (IHC) data. 2 As gene expression tests are not universally available in daily practice, IHC-based classification including the Ki-67 index is important to differentiate luminal A and B types. According to the 2013 and 2015 St Gallen guidelines, decisions on systemic adjuvant therapies of luminal cases with unclear indications are based on intrinsic subtype, determined by estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67 assessment. 2,3 Luminal A disease is characterized by a positive hormone receptor (HR), absence of HER2 amplification, and low Ki- 67 (,14%), and requires only endocrine therapy. On the other hand, in cases of luminal B/HER2 (HR þ, HER2, Ki %), luminal B/HER2 þ (HR þ, HER2 þ ), HER2-enriched (HR, HER2 þ ), and triple-negative disease (HR, HER2 ), Accepted for publication May 30, Published as an Early Online Release November 16, From the Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea (Dr Ahn); and the Department of Pathology, Ewha Womans University Medical Center, Seoul, Korea (Drs Lee, Cho, Park, and Sung). The authors have no relevant financial interest in the products or companies described in this article. Reprints: Sun Hee Sung, MD, PhD, Department of Pathology, Ewha Womans University Medical Center, 1071, Anyangcheon-ro, Yangcheon-gu, Seoul 07895, Korea ( sunhsung@ewha.ac.kr). chemotherapy is considered. 4 In the neoadjuvant chemotherapy setting, the Ki-67 index may serve as a predictive marker of response to chemotherapy and also serves as the primary or secondary endpoint. 5 7 Therefore, accurate estimation of the Ki-67 index is very important for proper management of patients with breast cancer. Multiple factors might affect Ki-67 staining and its measurement. These include type of biopsy, time to fixation, type of fixative, time in fixative, storage type, and measurement method. Regarding tissue type, the International Ki-67 in Breast Cancer working group 8 commented that both core biopsies and whole sections from excision are acceptable. Some studies 9,10 have suggested that whole sections may give higher Ki-67 scores than core biopsies. On the other hand, fixation is better controlled for core biopsies, allowing safer antigen preservation for IHC. 3 Fixation issues can frequently cause differences in the appearance of stained nuclei. 8 More rapidly fixed core biopsies consistently showed well-circumscribed, uniformly staining nuclei, whereas nuclei in whole sections often showed areas of highly variable staining. This variability did not disrupt scoring by manual assessment. However, it can be difficult to deal with in digital image analysis procedures. 8 For ER, PR, and HER2, IHC is recommended in preoperative biopsy specimens. In cases of negativity of ER, PR, and HER2 in the biopsy specimen, it is advisable to retest for them in the surgical specimen because of putative tumor heterogeneity. 3 However, there is no established guideline for Ki-67 measurement. In this study, we measured the Ki-67 index with a digital image analyzer in core needle biopsies and matched surgical specimens of breast cancer. Further- 364 Arch Pathol Lab Med Vol 142, March 2018 Ki-67 Index in Breast Cancer Ahn et al
2 Table 1. Patient Characteristics (N ¼ 89) Ki-67 Index Low (,14%), No. (%) High (14%), No. (%) Total No. Cases P Breast surgery types Partial mastectomy 20 (76.9) 48 (76.2) Total mastectomy 6 (23.1) 15 (23.8) 21 pt stage 1 21 (80.8) 27 (42.9) a 2 3 (11.5) 33 (52.4) (7.7) 3 (4.8) 5 pn stage 0 18 (69.2) 40 (63.5) a 0þ 2 (7.7) 5 (7.9) (19.2) 10 (15.9) (0) 4 (6.3) (3.9) 4 (6.3) 5 Pathology type Invasive ductal carcinoma 24 (92.3) 62 (98.4) Others 2 (7.7) 1 (1.6) 3 Estrogen receptor Positive 24 (92.3) 36 (57.1) Negative 2 (7.7) 27 (42.9) 29 Progesterone receptor Positive 23 (88.6) 32 (50.8) Negative 3 (11.5) 31 (49.2) 34 HER2 Positive 0 (0) 14 (22.2) Negative 26 (100) 49 (77.8) 75 a Analyzed by Fisher exact test. more, we evaluated the trend of Ki-67 index between 2 sample types and also analyzed discordant cases. MATERIALS AND METHODS Patient Population From March to July 2016, 147 patients underwent partial or total mastectomy at Ewha Womans Hospital (Seoul, Korea) for primary breast cancer. Preoperative core needle biopsy was performed for all patients using at least two 14-gauge cores with ultrasound guidance. Patients who were diagnosed with invasive tumor both in core needle biopsy and in surgical specimen were included. Patients who received neoadjuvant chemotherapy or any intervening therapy were excluded. After exclusion, a total of 89 pairs of core needle biopsies and surgical specimens were included in this study. These core needle biopsy samples included those of both inhouse patients (n ¼ 48) and outside-hospital patients (n ¼ 41). Inhouse core biopsy specimens were immediately immersed in 10% formalin. For the surgical excision specimens, the time to fixation was 0.2 to 3 hours, and the fixation time was 12 to 24 hours. This study was approved by the institutional review board of our institution, and the need for informed consent was waived. Immunohistochemistry Immunohistochemistry was performed on 5-lm slidesofforma- lin-fixed and paraffin-embedded archival tumor tissue. Antigen retrieval was performed in a micro-oven in citrate buffer ph 6 for 20 minutes. The Ki-67 antibody (clone MIB1, Dako, Glostrup, Denmark) was diluted 1:500, incubated for 25 minutes in a TechMate 500 plus (Dako), and visualized with diaminobenzidine. Immunohistochemistry for ER, PR, HER2, and Ki-67 was performed on core needle biopsy samples. Immunohistochemistry for ER, PR, and HER2 was selectively repeated on the surgical resection specimens; Ki-67 IHC was repeated on the surgical resection specimen for all cases. For HER2 2 þ cases, fluorescence in situ hybridization was performed using a PathVysion HER2 DNA Probe Kit (Vysis, Downers Grove, Illinois). The Allred score was used for ER and PR scoring, and scores from 3 to 8 were regarded as positive. 11 Hormone receptor positivity was defined by any ER or PR positivity. Image Analysis Ki-67 stained slides were captured digitally at a hot spot at 3200 magnification. One hot spot area was selected for each case, and the measured area was 0.27 mm 2. The Ki-67 labeling index was measured using digital image analysis software (Tissue Studio 64 Dual, version 3.5, Definiens, Munich, Germany). Image analysis was performed by one experienced pathologist (S.A.). The Definiens software is based on Definiens Cognition Network Technology and is object oriented, multi-scale, context driven, and knowledge based. 12 During the process of area selection, normal breast tissue and nontumor cells were manually excluded by the pathologist. 13 Despite area selection, some contamination with nontumor cells, including stromal and lymphoid cells, was inevitable. 13 In order to distinguish non carcinoma cell elements from carcinoma cell nuclei on the digitized image, nuclei with small areas (,32 lm 2 gross area, which was decided by a mean nuclear area of 50 infiltrating lymphocytes, 31.7 lm 2, and by mean nuclear area of 50 normal ductal cells, 31.1 lm 2 ) and spindle features (greater than 0.5 oval rate) were considered as lymphocytes, normal ductal cells, and stromal cell nuclei, respectively, and were excluded. 13 Statistical Analysis Statistical analysis was performed using SPSS version Contingency tables and v 2 tests were used to correlate Ki-67 results with clinicopathologic variables including pt and N stages and ER and HER2 statuses. The Ki-67 indexes of core needle biopsies and surgical specimens were compared by Student t test. RESULTS Patient Demographics and Clinicopathologic Features Clinicopathologic characteristics of the 89 patients are summarized in Table 1. Twenty-one patients underwent radical mastectomy, and 68 patients underwent partial Arch Pathol Lab Med Vol 142, March 2018 Ki-67 Index in Breast Cancer Ahn et al 365
3 mastectomy with lymph node dissection or sentinel node biopsy. The median tumor size was 2.1 cm (range, cm). Of 89 total patients, 24 (27%) had lymph node metastasis. The histologic type was invasive ductal carcinoma for 86 of 89 patients. The other 3 patients were diagnosed with metaplastic carcinoma, papillary carcinoma, and mucinous carcinoma, respectively. Estrogen receptor and PR were expressed in 60 (67.4%) and 55 cases (61.8%), respectively. The HER2 IHC was negative in 57 cases (64%), equivocal in 23 cases (25.8%), and positive in 9 cases (10.1%). Of 23 HER2 IHC equivocal cases, 5 showed HER2 amplification by fluorescence in situ hybridization. In IHC classification of the preoperative biopsy, the numbers of luminal A, luminal B/HER2 negative, luminal B/HER2 positive, HER2-positive, and triple-negative type cancers were 25 (28.1%), 28 (31.5%), 7 (7.9%), 7 (7.9%), and 22 (24.7%), respectively. Ki-67 index was associated with pt stage (P ¼.001), ER status (P ¼.001), PR status (P ¼.001), and HER2 status (P ¼.008) (Table 1). Ki-67 Index and IHC Subtype in Core Needle Biopsy and Matched Whole Resection Specimens The Ki-67 index was significantly higher in the core needle biopsy compared with the surgical specimen (P,.001), with a median absolute difference of 3.5% (Figure 1). The Ki-67 index in the core needle biopsy ranged from 0.30 to 78 (median, 21.0; mean, 25.58), whereas it ranged from 0.20 to 67 (median, 17; mean, 22.1) in the surgical specimen. When we applied 14% as a cutoff, 16 of 89 cases (18%) showed discrepancy (Table 2). Thirteen cases showed a high (14%) Ki-67 index in the core needle biopsy but a low (,14%) Ki-67 index in surgical samples. Twelve of these 13 cases were positive for ER, 3 of which were HER2 positive. In terms of IHC subtype, 9 discordant cases were classified as luminal B/HER2 in the core needle biopsy and as luminal A in the surgical specimen. On the other hand, 3 cases showed a low Ki-67 index in the core needle biopsy but a high Ki-67 index in surgical specimens. Of these cases, one case was triplenegative type, and another case was luminal B/HER2 þ type. The other case was classified as luminal A type in thecoreneedlebiopsyandasluminalb/her2 type in the surgical specimen. There were a total of 10 cases (11.2%) that showed discordant intrinsic subtypes between the core needle biopsy and its matched surgical specimen. Analysis of Discordant Cases For 16 discordant cases, the images used for digital image analysis and Ki-67 slides were reviewed again by 2 pathologists (S.A. and S.S.). Of 13 cases showing a higher Ki-67 index in the core needle biopsy (Figure 2, A), 7 revealed a poor staining pattern in surgical specimens (Figure 2, B). Six cases showed a good quality of Ki-67 staining in both the core needle biopsy and the surgical specimen. For these cases, a heterogeneous distribution of Ki-67 positive tumor cells was noted (Figure 3). There were 3 cases showing a higher Ki-67 index in the surgical specimen. Two cases showed a heterogeneous staining pattern. One patient underwent core needle biopsy (Figure 4, A) at a primary health care center, and the fixation quality was poor in the core needle biopsy specimen (Figure 4, B). DISCUSSION Accurate Ki-67 measurement is important for proper treatment and management of breast cancer patients in clinical practice. In particular, the Ki-67 index is used as a surrogate marker of luminal A and luminal B types in ERpositive and HER2-negative breast cancers, and 14% is currently used as a cutoff. 2 We analyzed the concordance of Ki-67 index in core needle biopsies and matched surgical specimens of breast cancer. All Ki-67 analysis was performed by digital image analyzer in a hot spot area. In our study, the core biopsy revealed a higher Ki-67 index compared with the surgical specimen. Previous studies investigating concordance between core needle biopsy and surgical specimens showed various results. 9,10,14 18 Although some studies showed a higher Ki-67 index in core biopsy specimens, 14,15 other studies showed a higher Ki-67 index in surgical specimens. 9,10 Most studies reported a moderate rate of concordance between the 2 tissue types. However, the discordance rates of Ki-67 index were higher than those of ER and HER2 stains. In our study investigating 89 pairs of core biopsy and surgical specimens, there were 13 cases with a high (14%) Ki-67 in the core biopsy specimen and a low (,14%) Ki-67 in the surgical specimen. Of note, most cases were ER positive, and there was some discordance of luminal A/B type classification between the core needle biopsy and the surgical specimen. The fixation issue in surgical specimens accounted for many discordant cases. The surgical specimens often showed incomplete fixation in the center with good fixation at the periphery, which led to better staining at the periphery than at the center. In poorly fixed surgical specimens, the MIB1 stained many fewer tumor cells than it did in core needle biopsy samples. Unlike core needle biopsy samples, surgical specimens are inevitably exposed to varying periods of ischemia during tumor removal. 14 This hypoxic damage could result in apoptosis of cancer cells in surgical samples, causing a lower proliferation index. 14 In addition, the fatty characteristic of breast tissue often leads to inadequate fixation in mastectomy specimens. Poor fixation causes not only a decreased number of positive tumor cells, but also poor staining of MIB1. In some mastectomy specimens, the MIB1 was stained very faintly, and the digital image analyzer failed to accurately interpret faint staining. In cases showing poor quality of staining of MIB1, staining of ER, PR, and HER2 showed relatively good quality in the same specimen. It is known that MIB1 is a sensitive marker that is largely influenced by tissue quality. 19 Although the threshold of detection was modified several times in the digital analyzer, accurate detection was not successfully achieved. In this case, manual analysis could be more accurate. A recent study reported that digital image analysis outperforms manual biomarker assessment in breast cancer. 20 However, caution is required in interpretation of weak or unsatisfactory staining in digital image analysis. On the other hand, we also experienced one case that showed a higher Ki-67 index in a surgical specimen due to poor staining quality in the core needle biopsy from an outside hospital. This result also emphasizes the importance of fixation in breast samples. Another major cause of discordance is intratumoral heterogeneity of the Ki-67 index in breast cancer. We measured the Ki-67 index in a hot spot area. In breast cancer, hot spot areas are usually located in the periphery of the tumor. Core needle biopsy contains considerably fewer 366 Arch Pathol Lab Med Vol 142, March 2018 Ki-67 Index in Breast Cancer Ahn et al
4 Figure 1. Ki-67 index in core needle biopsies and matched surgical specimens. Figure 2. A, Ki-67 index in core needle biopsy: 18%. B, Ki-67 index in surgical specimen: 9%. The poor fixation of surgical specimen caused weak MIB1 staining. Nuclei in whole sections often showed areas of highly variable staining (MIB1 stain, original magnification 3200). Figure 3. This tumor reveals a heterogeneous pattern of Ki-67 index. Tumor cells on the left side show a higher Ki-67 index compared with those on the right (MIB1 stain, original magnification 340). Figure 4. A, Ki-67 index in core needle biopsy: 13%. B, Ki-67 index in surgical specimen: 53%. The poor fixation of the biopsy specimen caused weak MIB1 staining (MIB1 stain, original magnification 3200). Arch Pathol Lab Med Vol 142, March 2018 Ki-67 Index in Breast Cancer Ahn et al 367
5 Case No. Ki-67 in Core Needle Biopsy Ki-67 in Surgical Specimen Table 2. Estrogen Receptor Analysis of Discordant Cases Progesterone Receptor HER2 Cause of Discordance Positive Positive Negative Poor fixation in surgical specimen Negative Negative Negative Poor fixation in surgical specimen Positive Positive Negative Poor fixation in surgical specimen Positive Positive Positive Poor fixation in surgical specimen Positive Positive Negative Heterogeneity of proliferation index Positive Positive Negative Heterogeneity of proliferation index Positive Positive Negative Poor fixation in surgical specimen Positive Positive Negative Heterogeneity of proliferation index Positive Positive Negative Poor fixation in surgical specimen Positive Positive Negative Poor fixation in surgical specimen Positive Negative Positive Heterogeneity of proliferation index Positive Positive Positive Heterogeneity of proliferation index Positive Positive Negative Heterogeneity of proliferation index Positive Positive Positive Heterogeneity of proliferation index Negative Negative Negative Poor fixation in core biopsy specimen Positive Positive Negative Heterogeneity of proliferation index tumor cells than surgical specimens and is acquired mostly from the central portion of the tumor. An agreement on Ki- 67 measurement methodology has not been reached. There is no consensus on which region to score or the superiority of a digital image analyzer versus manual analysis. Although some institutes adopt the average measurement, many institutes adopt the hot spot area measurement for the Ki-67 index. In our institute, we measured Ki-67 in a hot spot area using a digital image analyzer. It is known that Ki-67 index measured in a hot spot area shows a higher level of interobserver and intraobserver variability. 21 This study has several limitations. We did not perform gene expression tests in breast cancer. Therefore, the correlation of IHC-based subtype and gene expression based subtype was not determined. In addition, the prognostic significance of Ki-67 was not investigated because of the short follow-up period. A further large-scale study with long-term follow-up is warranted to investigate this issue and suggest an established guideline for Ki-67 measurement. In conclusion, we report a substantial discordance in the Ki-67 index between core needle biopsies and matched surgical specimens. We recommend that Ki-67 index measurement be measured in core needle biopsies and surgical specimens for accurate subtyping of breast cancer. Good fixation quality should be assured for accurate Ki-67 index measurement. References 1. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11(2): Ignatiadis M, Buyse M, Sotiriou C. St Gallen International Expert Consensus on the primary therapy of early breast cancer: an invaluable tool for physicians and scientists. Ann Oncol. 2015;26(8): Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(suppl 5):v8 v Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer Ann Oncol. 2011;22(8): Dowsett M, Smith IE, Ebbs SR, et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res. 2005;11(2, pt 2):951s 958s. 6. Penault-Llorca F, Andre F, Sagan C, et al. Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009;27(17): Hugh J, Hanson J, Cheang MC, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol. 2009;27(8): Dowsett M, Nielsen TO, A Hern R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst. 2011;103(22): Knutsvik G, Stefansson IM, Aziz S, et al. Evaluation of Ki67 expression across distinct categories of breast cancer specimens: a population-based study of matched surgical specimens, core needle biopsies and tissue microarrays. PLoS One. 2014;9(11):e Chen X, Sun L, Mao Y, et al. Preoperative core needle biopsy is accurate in determining molecular subtypes in invasive breast cancer. BMC Cancer. 2013;13: Collins LC, Botero ML, Schnitt SJ. Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases. Am J Clin Pathol. 2005;123(1): Baatz M, Zimmermann J, Blackmore CG. Automated analysis and detailed quantification of biomedical images using Definiens Cognition Network Technology. Comb Chem High Throughput Screen. 2009;12(9): Arihiro K, Oda M, Ohara M, et al. Comparison of visual assessment and image analysis in the evaluation of Ki-67 expression and their prognostic significance in immunohistochemically defined luminal breast carcinoma. Jpn J Clin Oncol. 2016;46(12): Romero Q, Bendahl PO, Klintman M, et al. Ki67 proliferation in core biopsies versus surgical samples a model for neo-adjuvant breast cancer studies. BMC Cancer. 2011;11: Iqbal S, Anderson TJ, Marson LP, Prescott RJ, Dixon JM, Miller WR. MIB-1 assessments in breast cancers. Breast. 2002;11(3): Kwok TC, Rakha EA, Lee AH, et al. Histological grading of breast cancer on needle core biopsy: the role of immunohistochemical assessment of proliferation. Histopathology. 2010;57(2): Ricci MD, Calvano Filho CM, Oliveira Filho HR, Filassi JR, Pinotti JA, Baracat EC. Analysis of the concordance rates between core needle biopsy and surgical excision in patients with breast cancer. Rev Assoc Med Bras (1992). 2012;58(5): Kim HS, Park S, Koo JS, et al. Risk factors associated with discordant Ki-67 levels between preoperative biopsy and postoperative surgical specimens in breast cancers. PLoS One. 2016;11(3):e Arima N, Nishimura R, Osako T, et al. The importance of tissue handling of surgically removed breast cancer for an accurate assessment of the Ki-67 index. J Clin Pathol. 2016;69(3): Stalhammar G, Fuentes Martinez N, Lippert M, et al. Digital image analysis outperforms manual biomarker assessment in breast cancer. Mod Pathol. 2016; 29(4): Chung YR, Jang MH, Park SY, Gong G, Jung WH; Korean Breast Pathology Ki-67 Study Group. Interobserver variability of Ki-67 measurement in breast cancer. J Pathol Transl Med. 2016;50(2): Arch Pathol Lab Med Vol 142, March 2018 Ki-67 Index in Breast Cancer Ahn et al
Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationImmunohistochemical classification of breast tumours
Immunohistochemical classification of breast tumours Workshop in Diagnostic Immunohistochemistry September 19 th - 21 th 2018 Anne-Vibeke Lænkholm Department of Surgical Pathology, Zealand University Hospital,
More informationA Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast
Original Research Article A Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast E. Rajesh Goud 1, M. Muralidhar 2*, M. Srinivasulu 3 1Senior
More informationImmunohistochemical Expression of Hormone Receptors and The Histological Characteristics of Biochemically Hormone Receptor Negative Breast Cancers
Breast Cancer Vol. 14 No. 1 January 2007 Original Article Immunohistochemical Expression of Hormone Receptors and The Histological Characteristics of Biochemically Hormone Receptor Negative Breast Cancers
More informationContemporary Classification of Breast Cancer
Contemporary Classification of Breast Cancer Laura C. Collins, M.D. Vice Chair of Anatomic Pathology Professor of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Outline
More informationPrognostic significance of stroma tumorinfiltrating lymphocytes according to molecular subtypes of breast cancer
Prognostic significance of stroma tumorinfiltrating lymphocytes according to molecular subtypes of breast cancer Hee Jung Kwon, Nuri Jang, Min Hui Park, Young Kyung Bae Department of Pathology, Yeungnam
More informationReporting of Breast Cancer Do s and Don ts
Reporting of Breast Cancer Do s and Don ts 7 th SGH Annual Breast Pathology Course Professor Michael Bilous Conjoint Professor Western Sydney University Consultant Pathologist, Australian Clinical Labs,
More informationBreast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience
Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C, Heidel RE, Desai P, McLoughlin J, Panella T, Bell
More informationSurgical Pathology Issues of Practical Importance
Surgical Pathology Issues of Practical Importance Anne Moore, MD Medical Oncology Syed Hoda, MD Surgical Pathology The pathologist is central to the team approach needed to manage the patient with breast
More informationLow ER+ Breast Cancer. Is This a Distinct Group? Nika C. Gloyeske, MD, David J. Dabbs, MD, and Rohit Bhargava, MD ABSTRACT
Low ER+ Breast Cancer Is This a Distinct Group? Nika C. Gloyeske, MD, David J. Dabbs, MD, and Rohit Bhargava, MD From the Magee-Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA.
More informationUK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin
UK Interdisciplinary Breast Cancer Symposium Should lobular phenotype be considered when deciding treatment? Michael J Kerin Professor of Surgery National University of Ireland, Galway and Galway University
More informationBrief Formalin Fixation and Rapid Tissue Processing Do Not Affect the Sensitivity of ER Immunohistochemistry of Breast Core Biopsies
Brief Formalin Fixation and Rapid Tissue Processing Do Not Affect the Sensitivity of ER Immunohistochemistry of Breast Core Biopsies Victoria Sujoy, MD, Mehrdad Nadji, MD, and Azorides R. Morales, MD From
More informationDiagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Pathology. AGO e. V. in der DGGG e.v. sowie in der DKG e.v.
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Pathology Pathology Versions 2004 2017: Blohmer / Costa / Fehm / Friedrichs / Huober / Kreipe / Lück / Schneeweis / Sinn /
More informationDr. dr. Primariadewi R, SpPA(K)
Curriculum Vitae Dr. dr. Primariadewi R, SpPA(K) Education : Medical Doctor from UKRIDA Doctoral Degree from Faculty of Medicine University of Indonesia Pathologist Specialist and Consultant from Faculty
More information# Best Practices for IHC Detection and Interpretation of ER, PR, and HER2 Protein Overexpression in Breast Cancer
#1034 - Best Practices for IHC Detection and Interpretation of ER, PR, and HER2 Protein Overexpression in Breast Cancer Richard W. Cartun, MS, PhD Andrew Ricci, Jr, MD Department of Pathology Hartford
More information2016 Korean Breast Cancer Society. All rights reserved. eissn
ORIGINAL ARTICLE J Breast Dis 2016 December; 4(2): 70-76 JBD Journal of Breast Disease Reliability of Core Needle Biopsy in Evaluating Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth
More informationGOALS AND OBJECTIVES BREAST PATHOLOGY
GOALS AND OBJECTIVES BREAST PATHOLOGY LEVEL: PGY2, PGY3, PGY5 A number of these rotations are introductory in nature, as they are major subspecialties, and are followed by two more blocks in PGY-3, during
More informationClinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy
Case Series Clinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy Ling Xu 1*, Fang Li 1,2*, Yinhua Liu 1, Xuening Duan 1, Jingming Ye 1,
More informationMolecular in vitro diagnostic test for the quantitative detection of the mrna expression of ERBB2, ESR1, PGR and MKI67 in breast cancer tissue.
Innovation for your breast cancer diagnostics Now valid ated on: -Roche cob as z 480 A nalyzer -Roche L ightcycle r 480 II - ABI 750 0 Fast -Versant kpcr Cyc ler PGR ESR1 MKI67 Molecular in vitro diagnostic
More informationFAQs for UK Pathology Departments
FAQs for UK Pathology Departments This is an educational piece written for Healthcare Professionals FAQs for UK Pathology Departments If you would like to discuss any of the listed FAQs further, or have
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Methodology The test is based on the reported 50-gene classifier algorithm originally named PAM50 and is performed on the ncounter Dx Analysis System
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY GENE EXPRESSION PROFILING WITH PROSIGNA What is Prosigna? Prosigna Breast Cancer Prognostic Gene Signature Assay is an FDA-approved assay which provides
More informationQuality Assurance and Quality Control in the Pathology Dept.
Quality Assurance and Quality Control in the Pathology Dept. Judith Sandbank M.D. Pathology Assaf-Harofeh Medical Center ISRAEL jsandbank@asaf.health.gov.il 2 nd IBDC, 9 th February, 2012 Pathology as
More informationProduct Introduction
Product Introduction Product Codes: HCL026, HCL027 and HCL028 Contents Introduction to HER2 2 HER2 immunohistochemistry 3 Cell lines as controls 5 HER2 Analyte Control DR IHC 7 HER2 Analyte Control DR
More informationOnly Estrogen receptor positive is not enough to predict the prognosis of breast cancer
Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors
More informationIs adjuvant chemotherapy necessary for Luminal A-like breast cancer?
JBUON 2018; 23(4): 877-882 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Is adjuvant chemotherapy necessary for Luminal A-like breast cancer?
More informationMolecular in vitro diagnostic test for the quantitative detection of the mrna expression of ERBB2, ESR1, PGR and MKI67 in breast cancer tissue.
Innovation for your breast cancer diagnostics PGR G ATA G C G A C G AT C G A A A G A A G T TA G ATA G C G A C G AT C G A A A G A A G T TA G ATA G C G A C G AT C G A A A G A A G T TA G ATA G C G A C ERBB2
More informationA Retrospective Analysis of Clinical Utility of AJCC 8th Edition Cancer Staging System for Breast Cancer
Elmer ress Original Article World J Oncol. 2017;8(3):71-75 A Retrospective Analysis of Clinical Utility of AJCC 8th Edition Cancer Staging System for Breast Cancer Hui Hu a, Wei Wei a, Xin Yi a, Ling Xin
More informationAre there the specific prognostic factors for triplenegative subtype of early breast cancers (pt1-2n0m0)?
Are there the specific prognostic factors for triplenegative subtype of early breast cancers (pt1-2n0m0)? Department of General Surgery, Anam Hospital, Korea University, College of Medicine, 126-, Anam-dong
More informationRadiation Therapy for the Oncologist in Breast Cancer
REVIEW ARTICLE Chonnam National University Medical School Sung-Ja Ahn, M.D. Adjuvant Tamoxifen with or without in Patients 70 Years of Age with Stage I ER-Positive Breast Cancer: Efficacy Outcomes (10
More informationReviewer's report. Version: 1 Date: 24 May Reviewer: Cathy Moelans. Reviewer's report:
Reviewer's report Title: Validation of HER2 testing with core needle biopsy specimens from primary breast cancers in terms of interobserver reproducibility and concordance with surgically resected specimens
More informationIntroduction. Wilfred Truin 1 Rudi M. H. Roumen. Vivianne C. G. Tjan-Heijnen 2 Adri C. Voogd
Breast Cancer Res Treat (2017) 164:133 138 DOI 10.1007/s10549-017-4220-x EPIDEMIOLOGY Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/55957 holds various files of this Leiden University dissertation Author: Dekker T.J.A. Title: Optimizing breast cancer survival models based on conventional
More informationEstrogen Receptor, Progesterone Receptor, and Her-2/neu Oncogene Expression in Breast Cancers Among Bangladeshi Women
Journal of Bangladesh College of Physicians and Surgeons Vol. 28, No. 3, September 2010 Estrogen Receptor, Progesterone Receptor, and Her-2/neu Oncogene Expression in Breast Cancers Among Bangladeshi Women
More informationAdjuvan Chemotherapy in Breast Cancer
Adjuvan Chemotherapy in Breast Cancer Prof Dr Adnan Aydıner Istanbul University, Oncology Institute aa1 Slide 1 aa1 adnan aydiner; 17.02.2008 15-Year Reductions in Recurrence and Disease-Specific Mortality
More informationRNA preparation from extracted paraffin cores:
Supplementary methods, Nielsen et al., A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor positive breast cancer.
More informationTriple Negative Breast Cancer
Triple Negative Breast Cancer Prof. Dr. Pornchai O-charoenrat Division of Head-Neck & Breast Surgery Department of Surgery Faculty of Medicine Siriraj Hospital Breast Cancer Classification Traditional
More informationExpression of androgen receptors in primary breast cancer
Annals of Oncology 21: 488 492, 2010 doi:10.1093/annonc/mdp510 Published online 3 November 2009 Expression of androgen receptors in primary breast cancer S. Park 1, J. Koo 2, H. S. Park 1, J.-H. Kim 1,
More informationAuthor(s) Emi; Hatanaka, Yutaka; Matsuno, Yoshihiro; Yamashita. The final publication is available at link.springer. Instructions for use
Title Prognostic significance of pathologic complete respo cancer Yoshioka, Tatsuya; Hosoda, Mitsuchika; Yamamoto, Mit Author(s) Emi; Hatanaka, Yutaka; Matsuno, Yoshihiro; Yamashita CitationBreast Cancer,
More informationVersion 2 of these Guidelines were drafted in response to published updated ASCO/CAP HER2 test Guideline Recommendations-
Introduction: These guidelines represent systematically developed statements to assist in the provision of quality assured HER2 testing in breast and gastric/ gastro-oesophageal carcinoma. They are based
More informationKristen E. Muller, DO, Jonathan D. Marotti, MD, Vincent A. Memoli, MD, Wendy A. Wells, MD, and Laura J. Tafe, MD
AJCP / Original Article Impact of the 2013 ASCO/CAP HER2 Guideline Updates at an Academic Medical Center That Performs Primary HER2 FISH Testing Increase in Equivocal Results and Utility of Reflex Immunohistochemistry
More informationMEDICAL POLICY. Proprietary Information of YourCare Health Plan
MEDICAL POLICY SUBJECT: HER-2 TESTING IN INVASIVE BREAST OR PAGE: 1 OF: 7 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases,
More informationA new way of looking at breast cancer tumour biology
A new way of looking at breast cancer tumour biology Contents Intrinsic subtypes of breast cancer 3 Gene expression assays 3 Basis of the Prosigna test 4 Information provided by Prosigna 5 The accuracy
More informationJournal of Breast Cancer
Journal of Breast Cancer ORIGINAL ARTICLE J Breast Cancer 215 June; 18(2): 149-159 Differences in Clinical Outcomes between Luminal A and B Type Breast Cancers according to the St. Gallen Consensus 213
More informationThe Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer
The Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer Laura Spring, MD Breast Medical Oncology Massachusetts General Hospital Primary Mentor: Dr. Aditya Bardia
More informationTemplate for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of the Breast
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of the Breast Version: Template Posting Date: January 2018 Includes requirements from the 2017 CAP Accreditation
More informationJournal of Breast Cancer
Journal of Breast Cancer ORIGINAL ARTICLE J Breast Cancer 211 March; 14(1): 33-38 The 7-Gene Prognostic Signature for Korean Breast Cancer Patients Kuk Young Na, Ku Sang Kim, Jeong Eon Lee 1, Hee Jeong
More informationRESEARCH COMMUNICATION. High Ki-67 Expression is a Poor Prognostic Indicator of 5-Year Survival in Patients with Invasive Breast Cancer
RESEARCH COMMUNICATION High Ki-67 Expression is a Poor Prognostic Indicator of 5-Year Survival in Patients with Invasive Breast Cancer Xue-Qin Yang 1,2, Fu-Bing Wang 1, Chuang Chen 1, Chun-Wei Peng 1,
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationResponse to Paclitaxel in Node-positive Triple Negative Breast Cancer
J Korean Surg Soc 2010;79:173-179 DOI: 10.4174/jkss.2010.79.3.173 원 저 Response to Paclitaxel in Node-positive Triple Negative Breast Cancer Department of Surgery, Kosin University College of Medicine,
More informationBreast cancer: Molecular STAGING classification and testing. Korourian A : AP,CP ; MD,PHD(Molecular medicine)
Breast cancer: Molecular STAGING classification and testing Korourian A : AP,CP ; MD,PHD(Molecular medicine) Breast Cancer Theory: Halsted Operative breast cancer is a local-regional disease The positive
More informationRetrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer.
Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer. Goal of the study: 1.To assess whether patients at Truman
More informationInterpretation of Breast Pathology in the Era of Minimally Invasive Procedures
Shahla Masood, M.D. Professor and Chair Department of Pathology and Laboratory Medicine University of Florida College of Medicine Jacksonville Medical Director, UF Health Breast Center Chief of Pathology
More informationCANCER. Clinical Validation of Breast Cancer Predictive Markers
Clinical Validation of Breast Cancer Predictive Markers David Hicks, MD Loralee McMahon, MS, HTL(ASCP) CANCER The human body is composed of billions of highly regulated cells Cancer cells no longer respond
More informationSurgical Therapy: Sentinel Node Biopsy and Breast Conservation
Surgical Therapy: Sentinel Node Biopsy and Breast Conservation Stephen B. Edge, MD Professor of Surgery and Oncology Roswell Park Cancer Institute University at Buffalo Dr. Roswell Park: Tradition in Cancer
More informationClaudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression
Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression Mona A. Abd-Elazeem, Marwa A. Abd- Elazeem Pathology department, Faculty of Medicine, Tanta
More informationApplications of IHC. Determination of the primary site in metastatic tumors of unknown origin
Applications of IHC Determination of the primary site in metastatic tumors of unknown origin Classification of tumors that appear 'undifferentiated' by standard light microscopy Precise classification
More informationMaram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine
Maram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine The most common non-skin malignancy of women 2 nd most common cause of cancer deaths in women, following
More informationBasement membrane in lobule.
Bahram Memar, MD Basement membrane in lobule. Normal lobule-luteal phase Normal lobule-follicular phase Lactating breast Greater than 95% are adenocarcinomas in situ carcinomas and invasive carcinomas.
More informationMolecular classification of breast cancer implications for pathologists. Sarah E Pinder
Molecular classification of breast cancer implications for pathologists Sarah E Pinder Courtesy of CW Elston Histological types Breast Cancer Special Types 17 morphological special types 25-30% of all
More informationThe Oncotype DX Assay A Genomic Approach to Breast Cancer
The Oncotype DX Assay A Genomic Approach to Breast Cancer Pathology: 20 th and 21 st Century Size Age Phenotype Nodal status Protein/Gene Genomic Profiling Prognostic & Predictive Markers Used in Breast
More informationBreast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital
Breast Cancer Earlier Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Switzerland Breast Cancer Earlier Disease Diagnosis and Prognosis Local Therapy Surgery Radiation therapy Adjuvant
More informationBreast cancer classification: beyond the intrinsic molecular subtypes
Breast cancer classification: beyond the intrinsic molecular subtypes Britta Weigelt, PhD Signal Transduction Laboratory CRUK London Research Institute Summary Breast cancer heterogeneity Molecular classification
More informationSystem-wide Ownership Group: Allina Health Breast Program Committee. Hospital Division Quality Council: August 2018
Oncology Clinical Service Line System-wide Consensus Guidelines: Evaluation and Management of Breast Lumpectomy and Mastectomy Specimens by Surgeons and Pathologists These guidelines apply to clinical
More informationThe Clinical Significance of. Triple-negative Phenotype on. Cancer Patients
The Clinical Significance of Triple-negative Phenotype on Prognosis of Young Age( 35) Breast Cancer Patients IM-KYUNG KIM Department of Medicine The Graduate School, Yonsei University The Clinical Significance
More informationImmunohistochemistry in Breast Pathology- Brief Overview of the Technique and Applications in Breast Pathology
SMGr up Immunohistochemistry in Breast Pathology- Brief Overview of the Technique and Applications in Breast Pathology Bhanumathi K Rao 1 * 1 Department of Biochemistry, JSS Medical College, a constituent
More informationGuideline. Associated Documents ASCO CAP 2018 GUIDELINES and SUPPLEMENTS -
Guideline Subject: ASCO CAP 2018 HER2 Testing for Breast Cancer Guidelines - Recommendations for Practice in Australasia Approval Date: December 2018 Review Date: December 2022 Review By: HER2 testing
More informationRadiation and DCIS. The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging
Radiation and DCIS The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging Einsley-Marie Janowski, MD, PhD Assistant Professor Department of Radiation Oncology
More informationOverview of breast cancerpatients and their prognostic factors treated in Baghdad teaching hospital/ oncology department in the year 2010
Original Article Overview of breast cancerpatients and their prognostic factors treated in Baghdad teaching hospital/ oncology department in the year 21 * DMRT clinical oncology, MSc. pathology. Summary:
More informationPaget's Disease of the Breast: Clinical Analysis of 45 Patients
236 Paget's Disease of the Breast: Clinical Analysis of 45 Patients Mingfian Yang Hao Long Jiehua He Xi Wang Zeming Xie Department of Thoracic Oncology, Cancer Center of Sun Yat-sen University, Guangzhou
More informationDepartment of Pathology, Loyola University Medical Center, Maywood, IL 60153, USA 2
Hindawi Publishing Corporation Pathology Research International Volume 2012, Article ID 947041, 7 pages doi:10.1155/2012/947041 Clinical Study The Effect of Cold Ischemia Time and/or Formalin Fixation
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationIntratumoral Heterogeneity in Breast Cancer: A Case Report and Molecular Discussion
Original Case Report Article Middle East Journal of Cancer; July October 20152018; 6(3): 9(4): 339-343 Intratumoral Heterogeneity in Breast Cancer: A Case Report and Molecular Discussion Akbar Safaei,
More informationCase Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.
Case Scenario 1 1/3/11 A 57 year old white female presents for her annual mammogram and is found to have a suspicious area of calcification, spread out over at least 4 centimeters. She is scheduled to
More informationSerum Ca 15-3: A Useful Tumor Marker in the Prognostication of Locally Advanced Breast Cancer
Original Article DOI: 10.21276/awch.1782 Serum Ca 15-3: A Useful Tumor Marker in the Prognostication of Locally Advanced Breast Cancer Mohd Rafey 1, Kafil Akhtar 1 *, Atia Z Rab 2 and Shahid A Siddiqui
More informationPMRT for N1 breast cancer :CONS. Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center
PMRT for N1 breast cancer :CONS Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center DBCG 82 b & c Overgaard et al Radiot Oncol 2007 1152 pln(+), 8 or more nodes removed Systemic
More informationHeather M. Gage, MD, Avanti Rangnekar, Robert E. Heidel, PhD, Timothy Panella, MD, John Bell, MD, and Amila Orucevic, MD, PhD
HER2 POSITIVE BREAST CARCINOMA IN THE PRE AND POST ADJUVANT ANTI-HER-2 THERAPY ERA: A SINGLE ACADEMIC INSTITUTION EXPERIENCE IN THE SETTING OUTSIDE OF CLINICAL TRIALS Heather M. Gage, MD, Avanti Rangnekar,
More informationNeo-adjuvant and adjuvant treatment for HER-2+ breast cancer
Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer Angelo Di Leo «Sandro Pitigliani» Medical Oncology Unit Hospital of Prato Istituto Toscano Tumori Prato, Italy NOAH: Phase III, Open-Label Trial
More informationEmerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer
Emerging Approaches for (Neo)Adjuvant Therapy for E+ Breast Cancer Cynthia X. Ma, M.D., Ph.D. Associate Professor of Medicine Washington University in St. Louis Outline Current status of adjuvant endocrine
More informationCorrelation Between GATA-3, Ki67 and p53 Expressions to Histopathology Grading of Breast Cancer in Makassar, Indonesia
Cancer Research Journal 2016; 4(3): 43-47 http://www.sciencepublishinggroup.com/j/crj doi: 10.11648/j.crj.20160403.11 ISSN: 2330-8192 (Print); ISSN: 2330-8214 (Online) Correlation Between GATA-3, Ki67
More informationPriti Lal, MD, 1 Paulo A. Salazar, 1 Clifford A. Hudis, MD, 2 Marc Ladanyi, MD, 1 and Beiyun Chen, MD, PhD 1. Abstract
Anatomic Pathology / DUAL- VS SINGLE-COLOR SCORING IN IMMUNOHISTOCHEMICAL AND FISH HER-2 TESTING HER-2 Testing in Breast Cancer Using Immunohistochemical Analysis and Fluorescence In Situ Hybridization
More informationIntroduction. Approximately 20% of invasive breast cancers
Introduction Approximately 2% of invasive breast cancers overexpress HER2 The current standard of care for neoadjuvant therapy is dual-targeted therapy with trastuzumab and pertuzumab plus chemotherapy
More informationHow to Use MRI Following Neoadjuvant Chemotherapy (NAC) in Locally Advanced Breast Cancer
Global Breast Cancer Conference 2016 & 5 th International Breast Cancer Symposium April 29 th 2016, 09:40-10:50 How to Use MRI Following Neoadjuvant Chemotherapy (NAC) in Locally Advanced Breast Cancer
More informationGábor CSERNI. 1. Bács-Kiskun County Teaching Hospital, Kecskemét 2. University of Szeged, Szeged
Lymphocytes infiltrant la tumeur (TIL) sur micro-biopsies et pièces opératoires Quel impact clinique? Quels moyens de mise en évidence? Comment restituer les résultats? TILs - Clinical impact / Evaluation
More informationBreast Cancer. Dr. Andres Wiernik 2017
Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk
More informationPathology Report Patient Companion Guide
Pathology Report Patient Companion Guide Breast Cancer - Understanding Your Pathology Report Pathology Reports can be overwhelming. They contain scientific terms that are unfamiliar and might be a bit
More informationQuestion 1 A. ER-, PR-, HER+ B. ER+, PR+, HER2- C. ER-, PR+, HER2- D. ER-, PR-, HER2- E. ER-, PR+, HER2+
Triple Negative Breast Cancer Laura C. Collins, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA Question 1 The tumor depicted on the next slide
More informationQuality assurance and quality control in pathology in breast disease centers
Quality assurance and quality control in pathology in breast disease centers Judith Sandbank M.D. Pathology Assaf-Harofeh Medical Center ISRAEL jsandbank@asaf.health.gov.il 1 st IBDC, 28 th January, 2011
More informationClinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy
Yang et al. World Journal of Surgical Oncology (2018) 16:51 https://doi.org/10.1186/s12957-018-1332-7 RESEARCH Open Access Clinical significance and prognostic value of receptor conversion in hormone receptor
More informationEvaluation of an Optimal Cut-Off Point for the Ki-67 Index as a Prognostic Factor in Primary Breast Cancer: A Retrospective Study
RESEARCH ARTICLE Evaluation of an Optimal Cut-Off Point for the Ki-67 Index as a Prognostic Factor in Primary Breast Cancer: A Retrospective Study Rumiko Tashima 1, Reiki Nishimura 2 *, Tomofumi Osako
More informationResearch Article Stromal Expression of CD10 in Invasive Breast Carcinoma and Its Correlation with ER, PR, HER2-neu, and Ki67
SAGE-Hindawi Access to Research International Breast Cancer Volume 20, Article ID 47957, 4 pages doi:0.406/20/47957 Research Article Stromal Expression of CD0 in Invasive Breast Carcinoma and Its Correlation
More informationInterobserver Variability of Ki-67 Measurement in Breast Cancer
Journal of Pathology and Translational Medicine 2016; 50: 129-137 ORIGINAL ARTICLE Interobserver Variability of Ki-67 Measurement in Breast Cancer Yul Ri Chung 1 Min Hye Jang 2 So Yeon Park 1,2 Gyungyub
More informationLecture 5. Primary systemic therapy: clinical and biological endpoints
Lecture 5 Primary systemic therapy: clinical and biological endpoints Valentina Guarneri, M.D., Ph.D. Primary systemic therapy in breast cancer Firstly introduced d into clinical i l practice in 70s for
More informationMorphological and Molecular Typing of breast Cancer
Morphological and Molecular Typing of breast Cancer Ian Ellis Molecular Medical Sciences, University of Nottingham Department of Histopathology, Nottingham University Hospitals NHS Trust Histological
More informationAssessment of Ki-67 for Predicting Effective Prognosis in Breast Cancer Subtypes
Biomedical Science Letters 2018, 24(1): 9~14 https://doi.org/10.15616/bsl.2018.24.1.9 eissn : 2288-7415 Original Article Assessment of Ki-67 for Predicting Effective Prognosis in Breast Cancer Subtypes
More informationThe Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer
The Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer Cancer The Biology Century Understanding and treating the underlying tumor biology Cancer genetic studies demonstrate
More informationAssessment of Breast Cancer with Borderline HER2 Status Using MIP Microarray
Assessment of Breast Cancer with Borderline HER2 Status Using MIP Microarray Hui Chen, Aysegul A Sahin, Xinyan Lu, Lei Huo, Rajesh R Singh, Ronald Abraham, Shumaila Virani, Bal Mukund Mishra, Russell Broaddus,
More informationSCIENCE CHINA Life Sciences
SCIENCE CHINA Life Sciences RESEARCH PAPER April 2013 Vol.56 No.4: 335 340 doi: 10.1007/s11427-013-4435-y Risk factors of recurrence in small-sized, node negative breast cancer in young women: a retrospective
More informationDetermination of HER2 Amplification by In Situ Hybridization. When Should Chromosome 17 Also Be Determined?
Anatomic Pathology / FISH f o r HER2: Wh e n to Use Ch r o m o s o m e 17 Determination of HER2 Amplification by In Situ Hybridization When Should Chromosome 17 Also Be Determined? John M.S. Bartlett,
More informationToru Nakamura 1, Takashi Fukutomi 1, Hitoshi Tsuda 2, Sadako Akashi-Tanaka 1, Kaneyuki Matsuo 1, Chikako Shimizu 1 and Kunihisa Miyakawa 3
Jpn J Clin Oncol 2000;30(10)453 457 Changes in Findings of Mammography, Ultrasonography and Contrast-enhanced Computed Tomography of Three Histological Complete Responders with Primary Breast Cancer Before
More information